Close menu




June 18th, 2020 | 09:12 CEST

Daimler, SAP, Triumph Gold - the changing world offers opportunities

  • Investments
Photo credits: pixabay.com

What is the next big trend or with what can you achieve a decent return in the next days, weeks, months or even years? These are the questions that investors are currently asking themselves because the world and the investment environment have changed dramatically since the outbreak of the Corona Pandemic. On the one hand, social and economic life around the globe came to a virtual standstill and, in contrast, the German leading index, for example, after a short and sharp correction, is now only around 10% below its all-time high of last February. Those who have so far missed the start of the recovery phase are now looking for opportunities that have attractive price potential in the second half of the year.

time to read: 2 minutes | Author: Mario Hose
ISIN: CA8968121043 , DE0007100000 , DE0007164600

Table of contents:


    Potential in the gold boom

    In the context of the Corona Pandemic, central banks around the world have adopted measures to ensure the stability of the financial system. The money supply was drastically increased and thus the course was set for a higher inflation rate. If you want to avoid the risk of currency devaluation, gold is a safe haven. The private banker John Pierpont (J.P.) Morgan is said to have once said that gold is money and everything else is credit. This proven truth may well be the beginning of a new trend.

    Each piece of gold is unique. This year gold production is expected to peak at around 118 million ounces. By 2029, production is expected to decline by up to 45%. The reserves of gold producers are also shrinking. In the period from 2012 to 2019 the reserves of the major producers were down 34% to 584 million ounces. Triumph Gold is exploring projects in the Canadian Yukon and already has the producer Newmont on board as a major shareholder. With further discoveries and a stable gold price, a takeover is a common exit strategy for shareholders.

    Loser of political planning

    The Daimler Group is currently in a dilemma. On the one hand, politicians have defined emission standards that limit the scope for action with regard to the product range and at the same time demand electromobility in which there is a widespread lack of charging and refueling facilities. The chicken/egg problem will be exacerbated by a lack of public understanding that electric mobility should be clean. As long as the source of the electricity is not cleaner than a combustion engine and the problem of disposal or recycling of batteries is not solved, sales are likely to decline and the lifetimes of combustion engines will be extended. The experiment to influence the climate will change Germany massively.

    Germany's heavyweight

    The German software company SAP is by far the most expensive company in the DAX. SAP's market value is currently around EUR 145 bn, well ahead of Linde with EUR 97 bn and Siemens with EUR 86 bn. Without SAP, many companies around the world can no longer function. The company has made itself simply irreplaceable with its software solutions. The latest project from SAP in cooperation with Deutsche Telekom is the Corona Warn App of the German government. SAP's stock combines vision, expertise and dividends.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read